As Biotechnology companies, Kezar Life Sciences Inc. (NASDAQ:KZR) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences Inc.	N/A	0.00	23.17M	-1.05	0.00
AVEO Pharmaceuticals Inc.	5.41M	25.58	5.33M	-0.20	0.00

Table 1 demonstrates Kezar Life Sciences Inc. and AVEO Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences Inc.	0.00%	0%	0%
AVEO Pharmaceuticals Inc.	-98.52%	48.1%	-69.9%

Liquidity

The Current Ratio and Quick Ratio of Kezar Life Sciences Inc. are 32.9 and 32.9 respectively. Its competitor AVEO Pharmaceuticals Inc.’s Current Ratio is 1.1 and its Quick Ratio is 1.1. Kezar Life Sciences Inc. can pay off short and long-term obligations better than AVEO Pharmaceuticals Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Kezar Life Sciences Inc. and AVEO Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Kezar Life Sciences Inc.	0	0	0	0.00
AVEO Pharmaceuticals Inc.	0	2	1	2.33

Competitively the consensus price target of AVEO Pharmaceuticals Inc. is $2, which is potential 100.94% upside.

Institutional & Insider Ownership

The shares of both Kezar Life Sciences Inc. and AVEO Pharmaceuticals Inc. are owned by institutional investors at 49.1% and 41.9% respectively. Insiders owned roughly 12.65% of Kezar Life Sciences Inc.’s shares. On the other hand, insiders owned about 0.3% of AVEO Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Kezar Life Sciences Inc.	-0.34%	13.07%	-20.02%	17.87%	0%	-14.19%
AVEO Pharmaceuticals Inc.	-15.19%	-19.85%	-72.92%	-80.67%	-80.4%	-64.96%

For the past year Kezar Life Sciences Inc. has stronger performance than AVEO Pharmaceuticals Inc.

Summary

AVEO Pharmaceuticals Inc. beats Kezar Life Sciences Inc. on 6 of the 10 factors.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.